Voyager Therapeutics (VYGR) Interest Expenses (2014 - 2026)
Voyager Therapeutics (VYGR) posted Interest Expenses of $40.2 million for Q1 2026, down 72.38% sequentially from $145.4 million in Q4 2025, and up 2666.18% YoY from $1.5 million in Q1 2025.
Voyager Therapeutics (VYGR) Interest Expenses (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Interest Expenses for 13 years, with the latest figure at $40.2 million in Q1 2026.
- Quarterly Interest Expenses rose 2666.18% year-over-year to $40.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.2 million (up 2666.18% YoY) and the FY2025 annual result came in at $145.4 million, up 37.32% from the prior year.
- Interest Expenses fell to $40.2 million in Q1 2026 per VYGR's latest filing, from $145.4 million in the prior quarter.
- Over five years, Interest Expenses peaked at $145.4 million in Q4 2025 and troughed at $1.3 million in Q4 2024.
- A 5-year average of $32.2 million and a median of $10.0 million in 2022 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2024: Interest Expenses surged 1067172.73% in 2022, then slumped 98.49% in 2024.
- Over 5 years, Interest Expenses stood at $117.4 million in 2022, then slipped by 29.63% to $82.6 million in 2023, then plunged by 98.49% to $1.3 million in 2024, then jumped by 11524.78% to $145.4 million in 2025, then sank by 72.38% to $40.2 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $40.2 million, $145.4 million, and $8.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Voyager Therapeutics | 201.32 Mn | 84.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.61 Mn |
| Jun 30, 2026 | 37.61 Mn |
| Mar 31, 2026 | 40.17 Mn |
| Mar 31, 2026 | 40.17 Mn |
| Dec 31, 2025 | 145.43 Mn |
| Dec 31, 2025 | 145.43 Mn |
| Sep 30, 2025 | 8.00 Mn |
| Sep 30, 2025 | 8.00 Mn |
| Jun 30, 2025 | 47.67 Mn |
| Jun 30, 2025 | 47.67 Mn |
| Mar 31, 2025 | 1.45 Mn |
| Mar 31, 2025 | 1.45 Mn |
| Dec 31, 2024 | 1.25 Mn |
| Dec 31, 2024 | 1.25 Mn |
| Sep 30, 2024 | 3.76 Mn |
| Sep 30, 2024 | 3.76 Mn |
| Jun 30, 2024 | 9.48 Mn |
| Jun 30, 2024 | 9.48 Mn |
| Mar 31, 2024 | 17.88 Mn |
| Mar 31, 2024 | 17.88 Mn |